Display Settings:

Format

Send to:

Choose Destination

    Diabetes Care. 2008 Nov;31(11):2116-7. Epub 2008 Aug 4.

    Neonatal diabetes with end-stage nephropathy: pancreas transplantation decision.

    Esmatjes E, Jimenez A, Diaz G, Mora M, Casamitjana R, Pérez de Nanclares G, Castaño L, José Ricart M.

    1Endocrinology and Diabetes Unit, Hospital Clínic Universitari, Barcelona, Spain. esmatjes@clinic.ub.es

    OBJECTIVE: To describe the diagnosis of a patient with neonatal diabetes who had been misdiagnosed with type 1 diabetes and referred to our hospital for pancreas and kidney transplantation because of end-stage renal disease. RESEARCH DESIGN AND METHODS: A diagnosis of neonatal diabetes was made after a molecular genetic study revealed a mutation in exon 34 of the ABCC8 gene. Pancreas transplantation was ill-advised. RESULTS: The patient was switched from insulin to glibenclamide 4 months after kidney transplantation, confirming that pancreas transplantation would not have been a good decision. CONCLUSIONS: This is the first report of a patient with neonatal diabetes who developed diabetic nephropathy that progressed to end-stage renal disease. This report illustrates that careful endocrinological evaluation, including molecular genetic studies, if necessary, is mandatory before a decision to perform a pancreas transplant is made.

    PMID: 18678608 [PubMed - indexed for MEDLINE]

    PMCID: 2571058

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Glyburide (Diabeta®, Glynase®, Micronase®, ...)

      Glyburide is used to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood), particularly in people whose diabetes cannot be contro...